Cargando…

The novel β2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells

PURPOSE: Proteasome-inhibiting drugs (PI) are gaining importance in hematologic oncology. The proteasome carries three proteolytically active subunits (β1, β2, β5). All established PI (bortezomib and carfilzomib), as well as experimental drugs in the field (dalanzomib, oprozomib, and ixazomib), by d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kraus, Johannes, Kraus, Marianne, Liu, Nora, Besse, Lenka, Bader, Jürgen, Geurink, Paul P., de Bruin, Gerjan, Kisselev, Alexei F., Overkleeft, Herman, Driessen, Christoph
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2015
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4515249/ https://www.ncbi.nlm.nih.gov/pubmed/26099967 http://dx.doi.org/10.1007/s00280-015-2801-0

Ejemplares similares

High Immunoproteasome Activity and sXBP1 in Pediatric Precursor B-ALL Predicts Sensitivity towards Proteasome Inhibitors
por: Besse, Lenka, et al.
Publicado: (2021)

The first-in-class alkylating HDAC inhibitor EDO-S101 is highly synergistic with proteasome inhibition against multiple myeloma through activation of multiple pathways
por: Besse, L, et al.
Publicado: (2017)

Nelfinavir augments proteasome inhibition by bortezomib in myeloma cells and overcomes bortezomib and carfilzomib resistance
por: Kraus, M, et al.
Publicado: (2013)

Proteasome inhibitor-adapted myeloma cells are largely independent from proteasome activity and show complex proteomic changes, in particular in redox and energy metabolism
por: Soriano, G P, et al.
Publicado: (2016)

Immunoproteasome Activity in Chronic Lymphocytic Leukemia as a Target of the Immunoproteasome-Selective Inhibitors
por: Besse, Andrej, et al.
Publicado: (2022)

Contribution of the Tumor Microenvironment to Metabolic Changes Triggering Resistance of Multiple Myeloma to Proteasome Inhibitors
por: Schwestermann, Jonas, et al.
Publicado: (2022)

Structure‐Based Design of Fluorogenic Substrates Selective for Human Proteasome Subunits
por: Maurits, Elmer, et al.
Publicado: (2020)

Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma
por: Besse, A, et al.
Publicado: (2018)

Structure-Based Design of Inhibitors Selective for Human Proteasome β2c or β2i Subunits
por: Xin, Bo-Tao, et al.
Publicado: (2019)

Novel Peptide-drug Conjugate Melflufen Efficiently Eradicates Bortezomib-resistant Multiple Myeloma Cells Including Tumor-initiating Myeloma Progenitor Cells
por: Byrgazov, Konstantin, et al.
Publicado: (2021)

The cytotoxic activity of carfilzomib together with nelfinavir is superior to the bortezomib/nelfinavir combination in non-small cell lung carcinoma
por: Besse, Lenka, et al.
Publicado: (2023)

Site-Specific Proteasome Inhibitors
por: Kisselev, Alexei F.
Publicado: (2021)

Recovery of proteasome activity in cells pulse-treated with proteasome inhibitors is independent of DDI2
por: Ibtisam, Ibtisam, et al.
Publicado: (2023)

High-dose carfilzomib achieves superior anti-tumor activity over low-dose and recaptures response in relapsed/refractory multiple myeloma resistant to low-dose carfilzomib by co-inhibiting the β2 and β1 subunits of the proteasome complex
por: Zhou, Xiang, et al.
Publicado: (2023)

The Use of Kappa Free Light Chains to Diagnose Multiple Sclerosis
por: Arneth, Borros, et al.
Publicado: (2022)

A clinically relevant pulse treatment generates a bortezomib-resistant myeloma cell line that lacks proteasome mutations and is sensitive to Bcl-2 inhibitor venetoclax
por: Downey-Kopyscinski, Sondra L., et al.
Publicado: (2022)

Combined Inhibition of p97 and the Proteasome Causes Lethal Disruption of the Secretory Apparatus in Multiple Myeloma Cells
por: Auner, Holger W., et al.
Publicado: (2013)

Addition of Standard Enzalutamide Medication Shows Synergistic Effects on Response to [(177)Lu]Lu-PSMA-617 Radioligand Therapy in mCRPC Patients with Imminent Treatment Failure—Preliminary Evidence of Pilot Experience
por: Rosar, Florian, et al.
Publicado: (2022)

Downregulation of 26S proteasome catalytic activity promotes epithelial-mesenchymal transition
por: Banno, Asoka, et al.
Publicado: (2016)

P45 HIGH-DOSE CARFILZOMIB ACHIEVES SUPERIOR ANTI-TUMOR ACTIVITY OVER LOW-DOSE AND RECAPTURES RESPONSE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA RESISTANT TO LOW-DOSE CARFILZOMIB BY CO-INHIBITING THE B2 AND B1 PROTEASOME SUBUNITS
por: Zhou, X., et al.
Publicado: (2023)

P855: SYNERGISTIC EFFICACY OF COMBINED SUMOYLATION AND PROTEASOME INHIBITION IN MULTIPLE MYELOMA
por: Keller, U., et al.
Publicado: (2022)

Synergistic effect of ibrutinib and CD19 CAR‐T cells on Raji cells in vivo and in vitro
por: Liu, Meijing, et al.
Publicado: (2020)

Proteasome inhibitors – molecular basis and current perspectives in multiple myeloma
por: Kubiczkova, Lenka, et al.
Publicado: (2014)

Non‐lethal proteasome inhibition activates pro‐tumorigenic pathways in multiple myeloma cells
por: Skorda, Aikaterini, et al.
Publicado: (2019)

Efficacy and safety of a novel synergistic drug candidate, CRx-102, in hand osteoarthritis
por: Kvien, T K, et al.
Publicado: (2008)

NEIL3-mediated proteasomal degradation facilitates the repair of cisplatin-induced DNA damage in human cells
por: Aliyaskarova, Umit, et al.
Publicado: (2023)

A Review of The Synergistic Effects of Curcumin with Proteasome Inhibitors in Multiple Myeloma Preclinical Models
por: Pandya, Shaunak K., et al.
Publicado: (2023)

Intraindividual comparison of [(177)Lu]Lu-DOTA-EB-TATE and [(177)Lu]Lu-DOTA-TOC
por: Hänscheid, Heribert, et al.
Publicado: (2021)

WA102
por: Peters, K
Publicado: (1995)

Run 102
por: Schnell, Wolfgang
Publicado: (1971)

Nelfinavir and lenalidomide/dexamethasone in patients with lenalidomide-refractory multiple myeloma. A phase I/II Trial (SAKK 39/10)
por: Hitz, F., et al.
Publicado: (2019)

Combination of Enzastaurin and Ibrutinib synergistically induces anti-tumor effects in diffuse large B cell lymphoma
por: He, Yizi, et al.
Publicado: (2019)

Proteasome Activity Profiling Uncovers Alteration of Catalytic β2 and β5 Subunits of the Stress-Induced Proteasome during Salinity Stress in Tomato Roots
por: Kovács, Judit, et al.
Publicado: (2017)

Ibrutinib-induced cardiomyopathy
por: Kyi, Htay Htay, et al.
Publicado: (2019)

Extrahepatic metabolism of ibrutinib
por: Rood, Johannes J. M., et al.
Publicado: (2020)

Modelling Proteasome and Proteasome Regulator Activities
por: Liepe, Juliane, et al.
Publicado: (2014)

Management of oral anticoagulation after cardioembolic stroke and stroke survival data from a population based stroke registry (LuSSt)
por: Palm, Frederick, et al.
Publicado: (2014)

Lapatinib–induced NF-kappaB activation sensitizes triple-negative breast cancer cells to proteasome inhibitors
por: Chen, Yun-Ju, et al.
Publicado: (2013)

The decay of $^{102}$Cd
por: Hnatowich, D J, et al.
Publicado: (1970)

The decay of $^{102}Cd$
por: Hnatowich, D J, et al.
Publicado: (1970)

Cannot write session to /tmp/vufind_sessions/sess_4s5jk6lfekgb8048bh2iuahek5